Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenR01Clinical trial: Not allowed

CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)

National Institutes of Health (NIH) · NIH Institute/Center · PAR-25-077

Source: Grants.gov · View original posting ↗

Award
Up to $300K
Deadline
Oct 16, 2026
Letter of intent
Mechanism
R01
Duration
Expected awards
4
Funding cycle
Standard NIH dates
Open date
Nov 1, 2024
Total funding
$300K total
Clinical trial
Not allowed
Established investigatorGovernmentSmall businessHigher educationNonprofitForeign entities

Funding context

16%of applications funded

Based on FY2024 NIH (all institutes) R01 applications (5,385 of 33,139 applications awarded).

Institute-specific data wasn’t available — showing the NIH-wide rate for this mechanism.

Payline: NIH discontinued percentile paylines for 2026 under its Unified Funding Strategy ↗ — scores are now weighed in context rather than against a fixed cutoff.

NIH-wide R01, all institutes.

Aggregate historical data by institute, mechanism, and fiscal year — context for planning, not a prediction for this opportunity. Source ↗

Research areas

Basic mechanisms & biologyTherapeutics & drug discovery

Auto-classified from the title and description (keyword-based) — may be imperfect.

Description

This announcement invites applications for basic research projects on chemical warfare agents, toxic industrial chemicals, and pesticides that have primary or secondary effects on the nervous system. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage, or shipping. Projects supported by this NOFO are expected to generate data that elucidate mechanisms of toxicity of these agents, possible new manifestations of toxic exposures, and potential new targets for therapeutic development.

Data notes: administering NIH institute could not be identified from the opportunity number.